Table 3. Clinical trials regarding to first-line chemoradiotherapy in I/II stage NK/T lymphoma.
| Study | Staging | No.of patients | Treatment regimen | ORR (%) | CR (%) | OS (%) | PFS (%) | Grade 3/4 toxicity (%) |
|---|---|---|---|---|---|---|---|---|
| Wang et al. [15] | IE=18 IIE=9 |
27 | GELOX plus radiation | 96.3 | 74.4 | 86(2-y) | 86(2-y) | Hematologic 33.3 Mucositis 15 |
| Kim et al. [16] | I=15 II=15 |
30 | Concurrent chemoradiotherapy plus VIPD | 100 | 73.3 | 86.3(3-y) | 85.2(3-y) | Neutrocytopenia 40 Nausea 3 |
| Yamaguchi et al. [17] | IE=22 IIE=11 |
27 | DeVIC plus radiation | 81 | 77 | 78(2-y) | 67(2-y) | Leukocytopenia 97 Neutrocytopenia 91 |
| Jiang et al. [18] | IE=13 Extended IE =7 IIE=6 |
26 | LVP plus radiation | 88.5 | 80.8 | 88.5(2-y) | 80.6(2-y) | Leukocytopenia 7.7 Mucositis 23.1 |
| This study | IE=14 Extended IE =29 IIE=23 |
66 | VDLP plus Concurrent chemoradiotherapy | 86.4 | 83.3 | 70.1(3-y) | 67.4(3-y) | Leukocytopenia 16.7 Thrombocytopenia 3.0 |
ORR, objective response rate; CR, complete response; OS, overall survival; PFS, progression-free survival.